3 results match your criteria: "Center for Cancer Research Liver Cancer Program[Affiliation]"
Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice.
Gastroenterology
January 2021
Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; National Cancer Institute, Center for Cancer Research Liver Cancer Program, Bethesda, Maryland. Electronic address:
Article Synopsis
- Nonalcoholic steatohepatitis (NASH) negatively impacts the effectiveness of immunotherapy against liver tumors in mice, leading to an increase in tumor growth due to a decrease in CD4 T cells.
- In experiments, while immunotherapies like M30 and aOX40 did inhibit tumor growth in normal mice, they were ineffective in those with steatohepatitis unless treatment with N-acetylcysteine was used to preserve CD4 T cells.
- The study highlights the role of CD4 T cells in tumor fighting and suggests that targeting steatohepatitis could improve responses to immunotherapy in liver cancer.
Gender disparity in HCC: Is it the fat and not the sex?
J Exp Med
May 2019
Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch and National Cancer Institute Center for Cancer Research Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
Men are more likely to develop hepatocellular carcinoma (HCC) than women, but it is not clear why. In this issue of , Manieri et al. (https://doi.
View Article and Find Full Text PDFAdjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy.
Hepatology
October 2019
Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Although patients undergo procedures with curative intent for early-stage hepatocellular carcinoma (HCC), up to 70% of patients may have disease recurrence in the liver at 5 years. Thus far, no therapy has proven to be effective in the adjuvant setting. Here, we discuss the application of immune-based therapies in the adjuvant setting for HCC, focusing on the underlying rationale for immunotherapies, which patients may benefit from an immune-based therapy, and what type of immune therapy should be implemented.
View Article and Find Full Text PDF